Journal
VACCINES
Volume 11, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/vaccines11111732
Keywords
SARS-CoV-2; vaccine; hACE2 transgenic mice; intranasal route; spike protein; cationic liposome; CpG-ODNs; heterologous immunity
Categories
Ask authors/readers for more resources
Mucosal vaccination is effective in protecting against SARS-CoV-2 infection. Intranasal administration of a liposomal vaccine containing SARS-CoV-2 spike protein and an adjuvant showed no toxicity and provided efficient protection in mice. Intranasal vaccination induced higher levels of neutralizing antibodies and IgA titers, and demonstrated efficacy against different variants of concern. Compared to intramuscular vaccination, intranasal administration resulted in better lung clearance of the virus and higher antibody production. The intranasal liposomal formulation also enhanced heterologous immunity induced by previous vaccination.
Mucosal vaccination appears to be suitable to protect against SARS-CoV-2 infection. In this study, we tested an intranasal mucosal vaccine candidate for COVID-19 that consisted of a cationic liposome containing a trimeric SARS-CoV-2 spike protein and CpG-ODNs, a Toll-like receptor 9 agonist, as an adjuvant. In vitro and in vivo experiments indicated the absence of toxicity following the intranasal administration of this vaccine formulation. First, we found that subcutaneous or intranasal vaccination protected hACE-2 transgenic mice from infection with the wild-type (Wuhan) SARS-CoV-2 strain, as shown by weight loss and mortality indicators. However, when compared with subcutaneous administration, the intranasal route was more effective in the pulmonary clearance of the virus and induced higher neutralizing antibodies and anti-S IgA titers. In addition, the intranasal vaccination afforded protection against gamma, delta, and omicron virus variants of concern. Furthermore, the intranasal vaccine formulation was superior to intramuscular vaccination with a recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 spike glycoprotein (Oxford/AstraZeneca) in terms of virus lung clearance and production of neutralizing antibodies in serum and bronchial alveolar lavage (BAL). Finally, the intranasal liposomal formulation boosted heterologous immunity induced by previous intramuscular vaccination with the Oxford/AstraZeneca vaccine, which was more robust than homologous immunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available